NCT03837093 - Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

March 3, 2021

Study Completion Date

November 6, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

ILT101

Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks

DRUG

Placebo

Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks

Trial Locations (1)

75013

Clinical Investigation Center Paris Est Hôpital Universitaire Pitié-Salpêtrière 83 bd de l'Hôpital 75013 Paris, Paris